As on Thursday, Novo Nordisk ADR (NYSE: NVO) started slowly as it slid -0.29% to $125.79, before settling in for the price of $126.16 at the close. Taking a more long-term approach, NVO posted a 52-week range of $75.56-$138.28.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The company of the Healthcare sector’s yearbook sales growth during the past 5- year span was recorded 14.25%. Meanwhile, its Annual Earning per share during the time was 16.48%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 24.70%. This publicly-traded company’s shares outstanding now amounts to $3.38 billion, simultaneously with a float of $3.38 billion. The organization now has a market capitalization sitting at $425.60 billion. At the time of writing, stock’s 50-day Moving Average stood at $126.66, while the 200-day Moving Average is $104.75.
Novo Nordisk ADR (NVO) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Novo Nordisk ADR’s current insider ownership accounts for 0.00%, in contrast to 9.19% institutional ownership.
Novo Nordisk ADR (NVO) Earnings and Revenue Records
If we go through the results of last quarter, which was made public on 12/31/2023, the company posted 0.64 earnings per share (EPS) for the quarter, besting the agreed prediction (set at 0.63) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.76 per share during the current fiscal year.
Novo Nordisk ADR’s EPS increase for this current 12-month fiscal period is 24.70% and is forecasted to reach 4.12 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will increase by 2.80% through the next 5 years, which can be compared against the 16.48% growth it accomplished over the previous five years trading on the market.
Novo Nordisk ADR (NYSE: NVO) Trading Performance Indicators
Let’s observe the current performance indicators for Novo Nordisk ADR (NVO). It’s Quick Ratio in the last reported quarter now stands at 0.64. The Stock has managed to achieve an average true range (ATR) of 2.74. Alongside those numbers, its PE Ratio stands at $46.56, and its Beta score is 0.44. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 12.63. Similarly, its price to free cash flow for trailing twelve months is now 35.30.
In the same vein, NVO’s Diluted EPS (Earnings per Share) trailing twelve months is recorded 2.70, a figure that is expected to reach 0.75 in the next quarter, and analysts are predicting that it will be 4.12 at the market close of one year from today.
Technical Analysis of Novo Nordisk ADR (NVO)
Through scrutinizing the latest numbers posted by the [Novo Nordisk ADR, NVO], it can be observed that its last 5-days Average volume of 3.85 million was lower the volume of 4.82 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 72.79% While, its Average True Range was 2.74.
Raw Stochastic average of Novo Nordisk ADR (NVO) in the period of the previous 100 days is set at 71.32%, which indicates a major rise in contrast to 57.39% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 21.17% that was lower than 27.79% volatility it exhibited in the past 100-days period.
